On the existence and function of galanin receptor heteromers in the central nervous system by Kjell Fuxe et al.
“fendo-03-00127” — 2012/10/24 — 14:27 — page 1 — #1
REVIEW ARTICLE
published: 26 October 2012
doi: 10.3389/fendo.2012.00127
On the existence and function of galanin receptor
heteromers in the central nervous system
Kjell Fuxe1*, Dasiel O. Borroto-Escuela1 ,Wilber Romero-Fernandez1, Alexander O.Tarakanov2,
Feliciano Calvo1, Pere Garriga3, MercéTena3, Manuel Narvaez4, Carmelo Millón4, Concepción Parrado5,
Francisco Ciruela6, Luigi F. Agnati 7,8, José A. Narvaez4 and Zaida Díaz-Cabiale4
1 Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden
2 St. Petersburg Institute for Informatics and Automation, Russian Academy of Sciences, Saint Petersburg, Russia
3 Centre de Biotecnologia Molecular, Departament d´Enginyeria Química, Universitat Politécnica de Catalunya, Barcelona, Spain
4 Department of Physiology, School of Medicine, University of Málaga, Málaga, Spain
5 Department of Histology, School of Medicine, University of Málaga, Málaga, Spain
6 Unitat de Farmacologia, Departament Patologia i Terapéutica Experimental, Universitat de Barcelona, Barcelona, Spain
7 Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena, Italy
8 Istituto di Ricovero e Cura a Carattere Scientiﬁco, Lido Venice, Italy
Edited by:
Hubert Vaudry, University of Rouen,
France
Reviewed by:
Wing-HoYung, Chinese University of
Hong Kong, Hong Kong
Joao C. Cardoso, University of
Algarve, Portugal
*Correspondence:
Kjell Fuxe, Department of
Neuroscience, Karolinska Institutet,
Retzius väg 8, 17177 Stockholm,
Sweden.
e-mail: kjell.fuxe@ki.se
Galanin receptor (GalR) subtypes 1–3 linked to central galanin neurons may form het-
eromers with each other and other types of G protein-coupled receptors in the central
nervous system (CNS). These heteromers may be one molecular mechanism for galanin
peptides and their N-terminal fragments (gal 1-15) to modulate the function of different
types of glia–neuronal networks in the CNS, especially the emotional and the cardiovascular
networks. GalR–5-HT1A heteromers likely exist with antagonistic GalR–5-HT1A receptor–
receptor interactions in the ascendingmidbrain raphe 5-HT neuron systems and their target
regions. They represent a novel target for antidepressant drugs. Evidence is given for the
existence of GalR1–5-HT1A heteromers in cellular models with trans-inhibition of the pro-
tomer signaling. A GalR1–GalR2 heteromer is proposed to be a galanin N-terminal fragment
preferring receptor (1-15) in the CNS. Furthermore, a GalR1–GalR2–5-HT1A heterotrimer is
postulated to explain why only galanin (1-15) but not galanin (1-29) can antagonistically
modulate the 5-HT1A receptors in the dorsal hippocampus rich in gal fragment binding
sites. The results underline a putative role of different types of GalR–5-HT1A heterore-
ceptor complexes in depression. GalR antagonists may also have therapeutic actions in
depression by blocking the antagonistic GalR–NPYY1 receptor interactions in putative
GalR–NPYY1 receptor heteromers in the CNS resulting in increases in NPYY1 transmission
and antidepressant effects. In contrast the galanin fragment receptor (a postulated GalR1–
GalR2 heteromer) appears to be linked to the NPYY2 receptor enhancing the afﬁnity of
the NPYY2 binding sites in a putative GalR1–GalR2–NPYY2 heterotrimer. Finally, putative
GalR–α2-adrenoreceptor heteromers with antagonistic receptor–receptor interactions may
be a widespread mechanism in the CNS for integration of galanin and noradrenaline signals
also of likely relevance for depression.
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INTRODUCTION
Galanin is a neuropeptide (Tatemoto et al., 1983) widely dis-
tributed in neurons within the central nervous system (CNS;
Jacobowitz et al., 2004). Three Galanin receptor (GalR) subtypes,
GalR1–3, have been cloned and belong to the rhodopsin sub-
family of G protein-coupled receptor (GPCR; Branchek et al.,
2000; Lundstrom et al., 2005; Mitsukawa et al., 2008). GalR1 and
GalR2 in particular are found in many regions of the CNS as
demonstrated with in situ hybridization, radioligand binding, and
immunohistochemical studies and have all a high afﬁnity for
galanin. GalR1 and GalR3 are coupled to Gi/o leading to inhi-
bition of adenylate cyclase (AC), increases in MAPK activity and
opening of G protein-coupled inwardly rectifying K+ channels.
GalR2 is coupled to Gq/11 and its activation leads to increases
in phospholipase C with formation of IP3 increasing intracellular
calcium levels and of diacylglycerol (DAG) with the subsequent
activation of the protein kinase C. These three GalR subtypes
are involved in a number of functions in the CNS modulat-
ing neuroendocrine, cardiovascular and mood regulation, pain
control, food intake, and seizure threshold (Lundstrom et al.,
2005; Mitsukawa et al., 2008). Galanin has also been demon-
strated to exert neurotrophic and neuroprotective actions. As
early as 1988 (Fuxe et al., 1988b) indications for the existence
GalR–5-HT1A receptor–receptor interactions were obtained in
rat limbic membranes and in 1994 (Mazarati et al., 1994) in
a neuropharmacological analysis results were obtained suggest-
ing interactions of GalRs with glutamate receptors in the dorsal
striatum.
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This review serves to summarize the indications that GalR
subtypes may form heteromers with each other and other types
of GPCRs in the CNS as a molecular mechanism to modulate
the function of different types of glia–neuronal networks in
the CNS.
RECEPTOR HETEROMERS AND THEIR ALLOSTERIC
RECEPTOR–RECEPTOR INTERACTIONS VIA THE RECEPTOR
INTERFACE
We began to test the hypothesis of intramembrane receptor–
receptor interactions in 1980–1981 in membrane preparations
of various CNS regions and found that neuropeptides could
modulate the binding characteristics, especially the afﬁnity of
the monoamine receptors, in a receptor subtype speciﬁc way
(Agnati et al., 1980; Fuxe et al., 1981, 1983). Thus, intramembrane
receptor–receptor interactions did exist in addition to indirect
actions via phosphorylation and changes in membrane poten-
tial. However, it took around 10 years before they began to
have an impact in the receptor ﬁeld. But the good news were
that the results were in line with earlier ﬁndings by Limbird
et al. (1975), showing negative cooperativity in beta-adrenergic
receptors, which could be explained by the existence of recep-
tor homodimers leading to receptor–receptor interactions. It
was also clear that adapter proteins could be involved in medi-
ating the receptor–receptor interactions in brain membranes.
A logical consequence for the indications of direct physical inter-
actions between neuropeptide and monoamine receptors, the
term heteromerization was introduced to describe a speciﬁc inter-
action between different types of GPCRs (see Zoli et al., 1993;
Fuxe et al., 2012a).
Fluorescence resonance energy transfer (FRET) and biolu-
minescence resonance energy transfer (BRET) methods gave
the evidence needed to demonstrate heteromers among class A
GPCRs. In FRET two putative proteins can, e.g., bear a “donor”
(CFP or GFP2) or an “acceptor” (YFP). If these two proteins
interact then the donor and acceptor ﬂuorophores are likely in
proximity (10 nm or less) and energy transfer between donor
and acceptor can occur after donor excitation by demonstration
of YFP emission. In BRET two putative proteins bear a “donor”
(Rluc) or an “acceptor” ﬂuorophore (YFP or GFP2). If these pro-
teins are in proximity they do interact. Then, a donor–acceptor
energy transfer can occur after Rluc substrate (h-coelenterazine)
oxidation. The bioluminescence formed can activate YFP
and YFP emission develops (Fernández-Dueñas et al., 2012;
Fuxe et al., 2012a).
More recently, evidence has been presented by means of in situ
proximity ligation assay (in situ PLA) that in HEK293 cells D2LR
can form heteromers with D4.7R and especially with D4.2R and
D4.4R (Borroto-Escuela et al., 2011). In situ PLA have the potential
to enable a fuller understanding of GPCR receptor–receptor and
could be highly suited to investigate GPCR heteromers in tissue,
providing new insights in basic biological mechanisms, heterore-
ceptor levels and their locations, e.g., in the brain (Borroto-Escuela
et al., 2012).
It is clear that allosteric mechanisms make possible the inte-
grative activity taking place intramolecularly in monomers and
intermolecularly in homomers and heteromers (see Fuxe et al.,
2010b). Allostery is a mode of long distance communication
between distal sites in proteins. There may or may not exist
a conformational change at the binding site by the allosteric
communication. The conformational change is only one of the
possible scenarios. We have preferred pathways which vary with
given conditions, through which the strain energy is released
from the allosteric site following a perturbation event which can
pass over the receptor interface into the other protomer of the
receptor homomer or heteromer (see Fuxe et al., 2010a). Kenakin
(2008) rightly regards “Seven TM receptors as Nature’s prototype
allosteric protein: de-emphasizing the geography of binding”. The
allosteric receptor–receptor interactions induced by activation of
one receptor protomer can inﬂuence the recognition, G protein-
coupling and signaling and trafﬁcking of the other protomers in
the receptor heteromer.
A high energy strength double arginine-phosphate electrostatic
interaction has been found in theA2AR–D2R heteromer by Ciruela
et al. (2004) and Woods et al. (2005) which possess a covalent-like
stability as demonstrated with mass spectrometry in combination
with collision-induced dissociation experiments and conﬁrmed
by pull-down techniques. Based on a mathematical approach,
Tarakanov and Fuxe (2010) have deduced, based on 48 pairs of
receptors that formornot formheterodimers, a set of triplet amino
acid homologies that may importantly participate in receptor–
receptor interactions with an origin from integrin triplets of
marine sponges and toll-like receptor triplets (Tarakanov et al.,
2012a,b). We show how such triplets of amino acid residues and
their “teams” may be utilized to construct a kind of code that
determines (and/or predicts) which receptors should or should
not form heterodimers. We propose a “guide-and clasp” manner
for receptor–receptor interactions where “adhesive guides” may
be the triplet homologies. Ciruela et al. (2004) showed an amaz-
ing stability of epitope–epitope electrostatic interaction based on
arginine phosphate. Thus, we should note that two main players
contain R (Arg): IDR and AAR. Others have distinct relationships
to negatively and positively charged amino acids.
The receptor heteromers due to the receptor–receptor interac-
tions (RRI) represent a new target for drugs since they allow inter
alia a higher selectivity in drug actions. Thus, in principle, it is pos-
sible to have not simply drugs acting as agonists, or partial agonists
or antagonists on a receptor A that is assembled in a heteromer.
Rather it is also possible to modulate receptor A through an action
on receptor B which belongs to the same heteromer and interacts,
via allosteric RRI, with receptor A (Figure 1). Against this back-
ground, a new ﬁeld for pharmacology can be considered. Let us list
the possible new opportunities to be investigated in a very simple
case that of A–B-receptor heterodimers with the aim to modulate
the recognition/decoding processes of receptor A. Due to the RRI
in the dimer it could be possible to use: (1) receptor B-agonists,
(2) receptor B-partial agonists, (3) receptor B-antagonists, and (4)
receptor B allosteric modulators. These treatments could change
the recognition/decoding process of:
(a) The complex endogenous ligands/receptor A.
(b) The complexes receptor A-agonist/receptor A, receptor A-
partial agonist/receptor A, or receptor A-antagonist/receptor
A or receptor A allosteric modulator/receptor A.
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FIGURE 1 | Intermolecular allosteric mechanisms of the GPCR homo/
heteromer and their receptor interface making possible molecular
integration of transmitter signals.Three-dimensional molecular models of
the sevenTM regions of two putative GPCR (A and B) were built by means of
the homology modeling program Accelrys Discovery Studio 2.5 (San Diego,
CA, USA) to show that dimerization of GPCR can result from either covalent
and non-covalent unions between receptor protomers. (Helix–helix
interaction) Seen from a lateral view, representation of the A(TM-IV/)–B(TM-V)
interaction in the A–B receptor heterodimer is shown. (Electrostatic
interactions) Illustration of positively charged arginine-rich epitope (red) in the
N-terminal part of the third intracellular loop of receptor A electrostatically
interacting with the negatively charged (blue) C-terminal epitopes of the
receptor B. These electrostatic interactions may represent important hot
spots in the receptor interface of some receptor heteromers like A2AR–D2R,
A2AR–D3R, and A2AR–D4R heteromers. Allosteric mechanisms make
possible the integrative activity taking place intramolecularly in monomers
or intermolecularly in homo/heteromers (arrow with two directions in the
interface). Intermolecular allosteric mechanisms take place through the
formation of different types of receptor homo/heteromers and receptor/
protein complexes which can change the function of an individual receptor
protomer present in a homomer or heteromer. One example of the novel
pharmacology created by heteromers is the use of heterobivalent ligands
containing an A pharmacophore and a B pharmacophore linked through a
spacer of variable length which may function as useful molecular probes for
targeting the A–B receptor heteromer and in this way counteracting or
enhancing the receptor–receptor interactions in these heteromers. Such
compounds may have a potential for use in pharmacotherapy of CNS
diseases.
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In the case of a trimer or even higher order oligomers that is of
a receptor mosaic (RM) we should consider especially
(a) Topological organization.
(b) Localization and route of the “Allosteric Pathways” inside the
RM.
(c) Possible existence of “Check-Points” along the allosteric
pathways.
POTENTIAL EXISTENCE OF GALANINR–5-HT1A HETEROMERS
WITH ANTAGONISTIC GalR–5-HT1A RECEPTOR–RECEPTOR
INTERACTIONS IN THE ASCENDING MIDBRAIN RAPHE 5-HT
NEURON SYSTEMS AND THEIR TARGET REGIONS. A NOVEL
TARGET FOR ANTIDEPRESSANT DRUGS
A substantial density of high afﬁnity GalRs was demonstrated in
the dorsal raphe by the Jacobowitz group in 1986 (Skoﬁtsch et al.,
1986) after having shown the existence of galanin IR cell bod-
ies in the dorsal raphe (DR) after colchicine treatment (Skoﬁtsch
and Jacobowitz, 1985). This work inspired the Fuxe group to per-
form intraventricular (ivt) injections with galanin and evaluate its
effects on regional 5-HT levels andmetabolism (Fuxe et al., 1988a).
In 1986 the coexistence of 5-HT and galanin IR in DR cell bodies
was found (Melander et al., 1986) and in 1990 only a proportion
of the 5-HT nerve cell bodies in the DR was found to costore
galanin and 5-HT IR after colchicine (Fuxe et al., 1990). Intra-
ventricular galanin reduced 5-HT metabolism in ventral limbic
cortex, hippocampal formation, and fronto-parietal cortex prob-
ably via direct inhibitory actions on DR 5-HT nerve cells reducing
their ﬁring rates (Fuxe et al., 1988a). These results for the ﬁrst time
suggested based on the 5-HT hypothesis of depression (see Carls-
son et al., 1968) that galanin, via actions on GalRs, mainly GalR
in the DR, may contribute to depression by reducing ﬁring in the
ascending 5-HT neurons (see also Kehr et al., 2002). Thus, GalR
antagonists may represent novel antidepressant drugs.
The sameyear itwas alsodiscovered in limbicmembraneprepa-
rations that galanin in nanomolar concentrations can reduce the
afﬁnity of postjunctional [3H]-5HT1A agonist binding sites sug-
gesting that galanin can reduce 5-HT1A recognition and probably
signaling in the limbic system (Fuxe et al., 1988b). This indicates
that galanin also via such actions can contribute to development
of a state of depression, since postjunctional 5-HT1A receptors
likely is one of the 5-HT receptors elevating mood upon activa-
tion (see Fuxe et al., 1991). This receptor has also been implicated
in the pathophysiology of depression based inter alia on analysis
of brain samples from depressed suicides (Lowther et al., 1997).
These results onGalRmodulation of 5-HT1A agonist binding sites
gave the ﬁrst indication that brain GalR/5-HT1A heteromers may
exist where GalRs antagonize postjunctional 5-HT1A recognition
and signaling via intramembrane receptor–receptor interactions
(Fuxe et al., 1990, 1991, 2008; Zoli et al., 1993). The antago-
nistic GalR/5-HT1A receptor interactions in putative receptor
heteromers represented a novel integrative mechanism in 5-HT
neurotransmission. The role of galanin in the modulation of 5-
HT neurotransmission became, however, more complex with the
observations that galanin can increase potassium-induced 5-HT
release from synaptosomal preparations (Martire et al., 1991). This
gave the ﬁrst indication there may also exist GalRs that increase
5-HT neurotransmission and thus may be beneﬁcial for treatment
of depression. In fact, it has recently been proposed that activation
of GalR2 can produce antidepressant actions (Lu et al., 2005; see
Lundstrom et al., 2005; Mitsukawa et al., 2008). However, the over-
all inhibitory inﬂuence of GalRs was in dominance (see Fuxe et al.,
1988a,b). The relevance of antagonisticGalR/5-HT1A interactions
for depression were discussed especially in the frame of the 5-HT
isoreceptor disbalance hypothesis of depression (see Fuxe et al.,
1977, 1991; Ogren et al., 1979) and the galanin-induced reduc-
tion of activity in the ascending 5-HT neurons (Fuxe et al., 1991).
GalRs counteract the postjunctional mood elevating 5-HT1A sig-
naling while the signaling over other subtypes of 5-HT receptors
like the 5-HT2-like receptors which may be blocked by classical
antidepressant drugs (Fuxe et al., 1977, 1991; Ogren et al., 1979)
were less affected. A behavioral correlate has been obtained to the
postjunctional antagonistic GalR/5-HT1A receptor interactions
(Razani et al., 2001). The activation of 5-HT1A receptors in mem-
brane preparations and in brain sections was in contrast found to
increase the afﬁnity of the GalRs in diencephalic and telencephalic
areas (Hedlund et al., 1991a). Thus, reciprocal intramembrane
receptor–receptor interactionsmay exist in putativeGalR/5-HT1A
heteromers where an activation of 5-HT1A receptors increases
GalR recognition and probably GalR signaling. Thus, if the 5-
HT1A receptor is regarded as a hub receptor and the GalR as the
accessory receptor in this receptor heteromer, it seemspossible that
the GalR mediates an inhibitory intramembrane feedback mecha-
nism to dampen overactivity in 5-HT1A receptor signaling (Fuxe
et al., 1988b, 1991; Hedlund and Fuxe, 1996). However, it is still
unknown which GalR subtype protomers are modulated by the
agonist-induced activation of the 5-HT1A protomer in the GalR–
5-HT1A heteromers. In other cases, however, the enhancement of
the GalR signaling may be the major action, allowing the 5-HT1A
protomer to bring down ﬁring in the raphe nuclei further due to
increased opening of the GalR regulated GIRK channels leading
to increased hyperpolarization (Hedlund et al., 1991b).
GalR–5-HT1A AUTORECEPTOR INTERACTIONS IN THE DORSAL RAPHE
5-HT CELL BODIES/DENDRITES
A time-dependent modulatory action by GalRs exist also on 5-
HT1A autoreceptors in the DR nerve cells (Razani et al., 2000).
Intraventricular galanin produces ﬁrst a rapid decrease of the
5-HT1A autoreceptor recognition within 10 min (reduction of
afﬁnity) in line with the ﬁndings at postjunctional 5-HT1A
receptors (Fuxe et al., 1998, 2008). Thus, intramembrane antag-
onistic GalR/5-HT1A autoreceptor interactions in putative GalR–
5-HT1A autoreceptor heteromers can be demonstrated at the
soma-dendritic level of the DR 5-HT nerve cells. This will, how-
ever, not increase their nerve cell ﬁring since galanin itself causes
hyperpolarization (Xu et al., 1998) and it may represent only an
intramembrane inhibitory feedback to avoid abnormal inhibition
of the DR 5-HT nerve cells.
However, this change in the 5-HT1A autoreceptor is followed
after 2 h by a delayed rise in 5-HT1A autoreceptor density proba-
bly through reduced internalization of the GalR/5-HT1A receptor
heteromers (Razani et al., 2000) and/or a galanin-induced increase
in maturation and insertion of these heteromers into the plasma
membrane. This was associatedwith a reduction of galaninmRNA
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levels and of 5-HT1AmRNA levels in theDR supporting this inter-
pretation. Thus, GalR antagonists may exert antidepressant effects
in the DR not only by blockade of GalR signaling but also via
blockade of the galanin elicited increase in 5-HT1A autoreceptor
density.
A major paper in pointing to a role of raphe GalRs in depres-
sion and for the use of GalR antagonists as novel antidepressant
drugs was published by Bellido et al. (2002). The discovery was
made of an increased density of GalRs in the DR of a genetic rat
model of depression based on the use of Flinders Sensitive Line
rats. This rise of GalR density was associated with a reduction of
galanin IR in the DR and an increase in the immobility time in the
forced swimming test. This may represent a primary disturbance
contributing to development of humandepression by reducing ﬁr-
ing in the ascending 5-HT pathways to the limbic system and the
diencephalon. These results emphasize the introduction of GalR
antagonists targeting the DR in treatment of depression. However,
the GalR subtypes appear to have a differential role in depression
as demonstrated by Bartfai and colleagues (Bartfai et al., 2004; Lu
et al., 2005; Barr et al., 2006). Thus, newly developed non-peptide
GalR3 antagonists exert antidepressant like activity in various
rodent models of depression (Barr et al., 2006). However, ﬂuoxe-
tine and electroconvulsive shock increase Gal mRNA levels in the
DR accompanied by increases in GalR2 receptor binding sites (Lu
et al., 2005) giving in contrast an antidepressant potential to GalR2
agonists. In fact, GalR2 may be the GalR involved in releasing 5-
HT from synaptosomal preparations (Martire et al., 1991). Based
on the available information it therefore seems that general GalR
andGalR3 antagonists have antidepressant properties while GalR2
antagonists may reduce mood.
EVIDENCE FOR THE EXISTENCE OF GalR1–5-HT1A
HETEROMERS IN CELLULAR MODELS
Previous work has established homodimerization and internal-
ization of GalR1 in living CHO cells using FRET and time
lapse confocal imaging (Wirz et al., 2005). Thus, GalR1 can
exist as a dimer in the plasma membrane which may undergo
desensitization and internalization upon agonist activation with
Gal1-29.
We have examined the possible existence of GalR–5-HT1A
heteromers in HEK-293 cells co-transfected with GFP2-tagged 5-
HT1A receptor andYFP-tagged GalR1 receptor using a proximity-
based FRET assay (Borroto-Escuela et al., 2010). In addition, a
novel bioinformatic approach to predict receptor–receptor inter-
face interactions was used (Tarakanov and Fuxe, 2010) together
with an analysis of signaling.
Upon co-expression of the 5-HT1A-GFP2 and GalR1-YFP
cDNA, a signiﬁcantly higher FRET signal was observed in com-
parison to the FRET signal obtained from a mixture of cells
individually expressing one of the two receptors. It represented a
constitutive heteromers since the observed FRET ratios were unal-
tered by agonist treatments. In cells co-expressing 5-HT1A-GFP2
and GalR1-YFP the two receptors became clearly co-distributed
in the plasma membrane at 48 h. And the speciﬁcity of this het-
eromer is indicated by the observation that expression of GalR2
does not block the FRET signal from developing in the 5-HT1A-
GFP2 and GalR1-YFP heteromer. Instead, the FRET signal is
increased. The understanding of the mechanism underlying this
increase may unravel whether the formation of a GalR1–GalR2–5-
HT1A higher-order heteromer (RM) takes place (Borroto-Escuela
et al., 2010).
Using CRE-luciferase and SRE-luciferase reporter assays it was
found that signaling by either the MAPK or AC pathways by these
heteromers results in a trans-inhibition phenomenon through
their interacting interface via allosteric mechanisms that block
the development of an excessive activation of Gi/o linked to
each of the receptors and an exaggerated inhibition of AC or
stimulation of MAPK activity (Figure 2; Borroto-Escuela et al.,
2010). These receptor heteromers may exist in the ascending
raphe 5-HT pathways in view of the demonstration of antago-
nistic GalR–5-HT1A receptor interactions in the limbic regions
and in the raphe reducing the afﬁnity of the 5-HT1A receptors
(see above).
Based on a bioinformatics approach, Tarakanov and Fuxe
(2010) have deduced a set of triplet homologies that may be
responsible for receptor–receptor interactions. This set consists of
two non-intersecting subsets: “pro-triplets” and “contra-triplets”.
Any pro-triplet appears as a homology in at least one heterodimer
but does not appear as a homology in any non-heterodimer.
The triplets SNS and LAR may have an important role in the
GalR–5-HT1A receptor interface. The locations of the triplet SNS
in the same transmembrane domains (TM7) of GalR1 and 5-
HT1A were shown. The locations of the triplet LAR were found
in the cytoplasmic (intracellular) domains of GalR1 (between
TM1 and TM2) and 5-HT1A (between TM5 and TM6). These
two triplets may therefore participate in the transmembrane and
intracellular components of the interface of the GalR1–5-HT1A
heteromer.
A GalR1–GalR2 HETEROMER IS PROPOSED TO BE A
GALANIN N-TERMINAL FRAGMENT PREFERRING
RECEPTOR (1-15) IN THE CNS
The three cloned receptors are known to show a higher afﬁnity
for Gal than for galanin N-terminal fragments like Gal (1-15)
(Branchek et al., 1998). A substantial further development of this
ﬁeld was the demonstration of speciﬁc N-terminal galanin frag-
ment, galanin (1-15) binding sites in the rat brain emphasizing
the powerful role of galanin fragments in galanin communica-
tion (Figure 3), especially in dorsal hippocampus, neocortex, and
striatum having few high afﬁnity galanin (1-29) binding sites
(Hedlund et al., 1992). Our hypothesis is that these N-terminal
Gal fragment preferring sites may be the result of formation of
GalR1/GalR2 heteromers leading to conformational changes in
their galanin recognition sites converting them into highly speciﬁc
galanin fragment binding sites with markedly reduced afﬁnity for
galanin (1-29) (Fuxe et al., 2008). It is of high interest that gal (1-
15) given intraventricularly in the rat has been found to produce
marked depression-like behavior in the FST and anxiogenic like
effects in the open ﬁeld (Millon Penuela et al., 2012).
POSTULATED EXISTENCE OF A GalR1–GalR2–5-HT1A
HETEROTRIMER
In agreement with above only galanin (1-15) but not galanin
(1-29) can antagonistically modulate the 5-HT1A receptors in
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FIGURE 2 | Recognition, signaling, and trafficking pathways and their
antagonistic receptor–receptor interactions in serotonin 5-HT1A and
galanin receptor (GalR1) heteromers in HEK293 cells and postulated
5-HT1A–GalR1–GalR2 trimers. (A) Schematic representation of the
antagonistic interactions observed after co-treatment with 5-HT1A receptor
agonist (8-OH-DPAT) and galanin (peptide 1-29) in co-transfected HEK293
cells. Signaling by either the mitogen-activated protein kinase (MAPK) or
adenylyl cyclase (AC) pathways by the 5-HT1A–GalR1 heteromers indicates a
trans-inhibition phenomenon through their interacting interface via allosteric
mechanisms that block the development of an excessive activation of Gi/o
with an exaggerated inhibition of AC or stimulation of MAPK activity. (B) A
study of the subcellular localization of tagged 5-HT1A and tagged GalR1 in
the presence of non-tagged GalR2 showed a co-distribution in the plasma
membrane of tagged 5-HT1A and tagged GalR1 already at 36 h in comparison
to cells expressing tagged 5-HT1A and tagged GalR1 only. In this case, the
tagged 5-HT1A receptor showed a more reticular distribution while tagged
GalR1 was mainly found in the plasma membrane. In the presence of GalR2 a
co-distribution in the plasma membrane of the tagged 5-HT1A and tagged
GalR1 is obtained already at 36 h and is maintained at 48 h. A facilitated
interaction of the GalR1–5-HT1A heterodimer into the plasma membrane by
expression of GalR2 can be explained based on the postulated receptor
mosaic (5HT1A–GalR1–GalR2), where the endoplasmic reticulum (ER)
trafﬁcking rate is higher than the trafﬁcking rate shown by the 5-HT1A–GalR1
heteromer. Available ﬁndings can be explained by postulating that a
GalR1–GalR2 heteromer is a galanin fragment preferring receptor which in
the postulated trimer with the 5-HT1A receptor exerts a strong antagonistic
receptor–receptor interaction with the 5-HT1A protomer at the level of
5-HT1A recognition.
the dorsal hippocampus and this effect may be blocked by a
known GalR antagonist M35 (Hedlund et al., 1994). Thus, a
RM of GalR1–GalR2/-5-HT1A receptors may exist especially in
the dorsal hippocampus, neocortex, the striatum, and the raphe
where galanin fragments may effectively antagonize postjunc-
tional and autoreceptor 5-HT1A recognition andmay function via
activation of the postulated GalR1/GalR2 heteromer (Figure 2).
Also a cross-inhibition of the GalR1–GalR2 heteromer by the
5-HT1A protomer in the trimer should be considered. The
GalR1–GalR2–5-HT1A heterotrimer may have a higher trafﬁck-
ing rate from the endoplasmic reticulum to the plasma membrane
than the GalR1–5-HT1A heteromer (Figure 2; Borroto-Escuela
et al., 2010).
Thus, known GalR antagonists should be putative antidepres-
sant drugs also by blocking galanin fragment preferring sites in
addition to galanin binding sites increasing postjunctional 5-
HT1A mediated 5-HT signaling and the ﬁring of the ascending
5-HT pathways (Hedlund et al., 1994; Fuxe et al., 1998). There-
fore, known GalR antagonists may have multiple targets and it
would be of high interest to develop an antagonist for treatment
of depression that selectively target the GalR1–GalR2 heteromer
postulated to be the galanin N-terminal fragment receptor.
Evidence has been presented thatN-terminal galanin fragments
can more strongly and more potently reduce postjunctional 5-
HT1A receptor recognition also in the ventral limbic cortex where
also high afﬁnity GalRs exist (Diaz-Cabiale et al., 2000a). These
effects were also blocked by a GalRs antagonist. The galanin
fragment preferring receptor may again be formed by the het-
eromerization of GalR1 and GalR2, since they are known to be
present here like in the dorsal hippocampus (O’Donnell et al.,
1999). The results underline an important role of different types
of GalR–5-HT1A heteroreceptor complexes in depression.
POTENTIAL EXISTENCE OF GalR–NPYY1 RECEPTOR
HETEROMERS IN THE NUCLEUS TRACTUS SOLITARIUS
(NTS), THE HYPOTHALAMUS AND THE DORSAL RAPHE WITH
ANTAGONISTIC GalR–NPYY1 RECEPTOR INTERACTIONS
In a series of papers by Diaz-Cabiale and colleagues (Diaz-Cabiale
et al., 2006, 2011; Parrado et al., 2007) evidence has been obtained
for an antagonistic GalRmodulation of NPY receptormechanisms
suggesting the existence of GALR–NPYY1 interactions involving a
likely reduction of NPYY1 receptor agonist afﬁnity probably tak-
ing place inGalR/NPYY1 receptor heteromers (Figure 4A) inNTS,
hypothalamus, and DR (Diaz-Cabiale et al., 2006, 2011; Parrado
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FIGURE 3 |The unknown signaling of the postulated galanin fragment preferring receptor (GalR1–GalR2 heteromer) is compared with the signaling
of the GalR1 and GalR2 homomers.
et al., 2007). The results open up the possibility that GalR/NPYY1
receptor–receptor interactions in putative heteromers is a frequent
phenomenon in CNS with implications for the integrative func-
tions of galanin and NPY in these regions. Thus, the GalR subtype
involved has not been determined. This interaction may be based
on a GalR/NPYY1 receptor heteromerization where the galanin
induced conformational change in theGalR can cause a conforma-
tional change in theNPYY1 receptor via theGalR/NPYY1 interface
leading to reducedNPYY1 recognition andGprotein coupling and
thus to reduced NPYY1 receptor signaling.
In the NTS (Diaz-Cabiale et al., 2006) the results suggest the
existence of antagonistic GalR–NPYY1 receptor interactions in
cardiovascular regions of this nucleus, reducing NPYY1 signaling
and thus vasodepressor activity leading to enhanced vasopressor
and tachycardic actions of GalR activation in the NTS.
In the hypothalamus (Parrado et al., 2007) evidence was, for
the ﬁrst time, obtained that GalR activation signiﬁcantly reduced
the NPYY1 receptor agonist binding in the hypothalamus without
effects on NPYY2 receptor agonist binding. These GalR–NPYY1
receptor interactions have physiological implications since the
food intake induced by the NPYY1 receptor agonist is blocked
by galanin. The changes observed on c-Fos expression support the
hypothesis that GalR activation modulates the response elicited by
the NPYY1 agonist.
In the DR we may postulate, on the basis of the galanin-
induced decrease in NPYY1 binding, an inhibitory GalR/NPYY1
receptor–receptor interaction that modulates behavioral func-
tions associated with mood and motivation. Behavioral and
neurochemical studies support a role of galanin and NPY in
mood disorders and GalR1-3 and NPYY1 receptors have been
the receptors implicated in depression with GalR subtype speciﬁc
antagonists and NPYY1 agonists having an antidepressant role (Lu
et al., 2005; Lundstrom et al., 2005; Ishida et al., 2007; Jimenez-
Vasquez et al., 2007; Fuxe et al., 2008). The decrease of NPYY1
agonist binding induced by galanin and the demonstrated cross-
inhibition of c-Fos expression in the dorsal raphe upon GalR and
NPYY1 agonist co-activation provides one possible basis for the
use of synergistic interactions of GalR subtype speciﬁc antagonists
and NPYY1 receptor agonists as a strategy for treatment of depres-
sion. Thus, GalR antagonists may also have therapeutic actions
in depression by blocking the antagonistic GalR–NPYY1 recep-
tor interactions resulting in increases in NPYY1 transmission and
antidepressant effects.
In the amygdala (Parrado et al., 2007) we may instead on the
basis of the galanin-induced increase in NPYY1 binding postulate
a facilitatory GalR/NPYY1 receptor interaction (Figure 4B) that
could be expected to produce anxiolytic actions. Behavioral stud-
ies support a role of galanin and NPY in reducing anxiety in the
amygdala and GalRs, NPYY1, and NPYY5 have been the receptors
implicated in this effect (see Moller et al., 1999; Heilig, 2004). The
increase of NPYY1 binding induced by galanin in this study pro-
vides a possible basis for synergistic interactions of GalR agonists
and NPYY1 receptor agonists in counteracting anxiety behavior.
The differential modulation of NPYY1 binding by galanin in the
hypothalamus and in the amygdala could be explained by inter
alia the involvement of different GalR subtypes in the interac-
tion with the NPYY1 receptor in the hypothalamus and amygdala,
respectively. It may also be that the same GalR subtype and NPY
receptor subtypes are involved in the two areas but they may be
part of different RMs (cluster of multiple receptors; higher order
heteromers) leading to altered GalR/NPYY1 interactions in the
two areas due to differences in the multiple receptor–receptor
interactions (Rimondini et al., 1999) in discrete RMs (Agnati et al.,
1982, 2003; Fuxe et al., 2010a,b). Thus, in this way the GalR may
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FIGURE 4 | Different types of postulated GalR heteromers and
Gal-fragmentR heteromers (postulated heterotrimers) and their
allosteric receptor–receptor interactions. Galanin receptor (GalR)
subtypes1-3 linked to central galanin neurons may form heteromers with
each other and other types of GPCRs in the CNS. These heteromers may
be one molecular mechanism for galanin peptides and their N-terminal
fragments (galanin 1-15) to modulate the function of different types of
glia–neuronal networks in the CNS, especially the emotional and the
cardiovascular networks. The allosteric receptor–receptor interactions
induced constitutively or by activation of one receptor protomer can inﬂuence
the recognition, G protein coupling, signaling and trafﬁcking of the other
protomers in the receptor heteromer. (A) NPYY1–GalRs heteromers likely
exist with antagonistic NPYY1–GalR receptor interactions involving a
reduction of NPYY1 receptor agonist afﬁnity probably taking place in
postulated GalR/NPYY1 receptor heteromers in NTS, hypothalamus, and
dorsal raphe. GalR antagonists may also have therapeutic actions in
depression by blocking the antagonistic GalR–NPYY1 receptor interactions in
putative GalR–NPYY1 receptor heteromers in the CNS resulting in increases
in NPYY1 transmission and antidepressant effects. (B) In contrast, in the
amygdala a facilitatory GalR/NPYY1 receptor interaction, likely involving
another GalR subtype than in A, is postulated based on the increase of
NPYY1 binding induced by GalR activation in this region expected to
produce anxiolytic actions. (C) Putative GalR–α2-adrenoreceptor
heteromers with antagonistic receptor–receptor interactions reducing α2
function may be a widespread mechanism in the CNS for integration of
galanin and noradrenaline signals, also of likely relevance for depression.
(D) Galanin fragment preferring receptor (a postulated GalR1–GalR2
heteromer) appears to be linked to the NPYY2 receptor enhancing the
afﬁnity and signaling of the NPYY2 receptor via unknown signaling
pathways in a putative GalR1–GalR2–NPYY2 heterotrimer; a reduction of Gi/o
signaling may contribute. (E) Furthermore, the postulated GalR1–GalR2
heteromer, a postulated galanin N-terminal fragment preferring receptor
(1-15), appears to be linked also to the AT1R in a postulated AT1R–GalR1–
GalR2 receptor mosaic enhancing the signaling of the AT1R within the NTS
via unknown signaling pathways; a reduction of Gi/o signaling may
contribute.
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reduce NPYY1 signaling in the hypothalamus and increase it in
the amygdala.
POSTULATED EXISTENCE OF A GalR1–GalR2–NPY Y2
HETEROTRIMER IN THE NTS
The presence of speciﬁc binding sites for the galanin fragment
1-15 in the nuclei involved in central cardiovascular regulation
has been described (Hedlund et al., 1992). In the brainstem a
high density of these galanin (1-15) binding sites appears within
the NTS, supporting the hypothesis of the existence of a recep-
tor with a higher afﬁnity for the N-terminal fragment than for
galanin (Diaz-Cabiale et al., 2005b). We have proposed (see above)
that these N-terminal galanin fragment preferring sites may be
the result of formation of GalR1/GalR2 heteromers leading to
conformational changes in their galanin recognition sites con-
verting them into highly speciﬁc galanin fragment binding sites
with markedly reduced afﬁnity for galanin (Fuxe et al., 2008).
As a matter of fact galanin and N-terminal fragment galanin (1-
15) have speciﬁc and different roles (hypotensive and vasopressor
responses, respectively) in cardiovascular regulation (Diaz-Cabiale
et al., 2005b). The N-terminal fragment galanin (1-15) antago-
nized the cardiovascular effects of galanin (Narvaez et al., 1994)
and galanin fragment (1-15) but not galanin decreases barore-
ceptor reﬂex sensitivity (Diaz et al., 1996). Galanin and galanin
(1-15) also stimulate the expression of c-Fos with different tem-
poral and spatial proﬁles, especially in the NTS and in the
ventrolateral medulla (Marcos et al., 2001). The GalR antago-
nist M40 is able to block the cardiovascular responses elicited
by the N-terminal fragment galanin (1-15) (Narvaez et al., 1994)
giving evidence that regular GalR antagonists also can block the
galanin fragment preferring receptors (postulated GalR1–GalR2
heteromer).
NPY operates in central cardiovascular regulation through
the NPYY1 and Y2 receptor subtypes. Leu31Pro34NPY, a spe-
ciﬁc NPYY1 receptor agonist, microinjected into the NTS elic-
its vasodepressor and bradycardic responses (Yang et al., 1993),
whereas the injection of the NPY C-terminal fragment (13-36), a
speciﬁc NPYY2 receptor agonist, leads to vasopressor responses at
low doses (Aguirre et al., 1990; Yang et al., 1993). In the study of
Diaz-Cabiale et al. (2010) the co-injection of threshold doses of
galanin (1-15) and of the NPYY2 agonist resulted in an increase
of MAPK of the same magnitude as observed with threshold doses
of NPY and galanin (1-15). Galanin (1-15) was also found to
speciﬁcally increase the NPYY2 agonist binding in the NTS with-
out inducing any effect on NPYY1 agonist binding (Diaz-Cabiale
et al., 2010). The increase by galanin (1-15) of the NPYY2 ago-
nist binding may indicate a galanin (1-15)-induced increase of
Y2 receptor afﬁnity in the NTS, since the concentration of the
NPYY2 agonist used (25 pM) is in the range of the Kd value, where
mainly afﬁnity changes affect the binding level. This interaction
may be based onGalR1–GalR2–NPYY2 receptor heteromerization
(Figure 4D) where the galanin (1-15) induced conformational
change in the GalR1–GalR2 heteromer via the interface with
NPYY2 can cause a conformational change in the NPYY2 recep-
tor leading to increased NPYY2 recognition and switching of G
protein coupling likely to Gq and thus to increased novel NPYY2
receptor signaling producing the vasopressor activity (Figure 4D;
Diaz-Cabiale et al., 2010). These results illustrate the high impact
of the allosteric receptor–receptor interactions in heteromers
in the integrative mechanisms responsible for the organization
of the cardiovascular responses from the local circuit level of
the NTS.
POSTULATED EXISTENCE OF GalR1–GalR2–AT1
HETEROTRIMER IN THE NTS
Galanin (1-15)/angiotensin II (Ang II) interactions have also
been observed in central cardiovascular control (Diaz-Cabiale
et al., 2005a). Thus, intracisternal co-injections of threshold doses
of Ang II with galanin (1-15) induce a signiﬁcant vasopressor
response that was maintained during the whole recording period,
without any signiﬁcant effect on heart rate. This response was
blocked by the AT1 speciﬁc antagonist DuP753 (Diaz-Cabiale
et al., 2005a). These data suggest the existence of a synergis-
tic interaction between Ang II and galanin (1-15), in which
the AT1 and Gal receptor subtypes participate. It may involve
allosteric receptor–receptor interactions in a GalR1–GalR2–AT1
heterotrimer (Figure 4E) within the NTS and switching of the
AT1R to Gq/11 mediated signaling.
POSTULATED EXISTENCE OF GalR–α2 ADRENORECEPTOR
HETEROMERS IN THE CNS
This proposal is inter alia based on the effects of galanin on
α2-adrenoreceptor activation were evaluated on central cardio-
vascular regulation in the NTS using also quantitative receptor
autoradiography (Diaz-Cabiale et al., 2000b). Central adminis-
tration of threshold doses of galanin together with an effective
vasodepressor dose of the α2-adrenoreceptor agonist clonidine
was found to induce a rapid vasopressor and tachycardic response.
On the contrary, the co-injection of threshold doses of clonidine
and N-terminal galanin fragment (1-15) did not result in any sig-
niﬁcant cardiovascular change (Diaz-Cabiale et al., 2000b). These
functional ﬁndings suggest that galanin, but not galanin fragment
(1-15), antagonizes α2-adrenoreceptor signaling via a GalR–α2-
adrenoreceptor interaction in a postulated heteromer built up of
these receptor protomers (Figure 4C). TheGalR subtypes involved
in these heteromers are presently unknown.
Quantitative receptor autoradiography supported this view
since galanin decreased the afﬁnity of the α2-adrenoreceptor
agonist [3H]p-aminoclonidine in the NTS and also increased
signiﬁcantly the density of the α2-adrenoreceptor agonist bind-
ing sites. These effects disappeared in presence of the speciﬁc
GalR antagonist M35, demonstrating that this action is a direct
consequence of GalR activation by galanin (Diaz-Cabiale et al.,
2000b, 2005b). Galanin also reduced the afﬁnity of the α2-adreno-
receptor agonist [3H]p-aminoclonidine in the tel- and dien-
cephalon which was also blocked by the speciﬁc receptor
antagonist M35 (Diaz-Cabiale et al., 2001). Thus, GalR–α2-
adrenoreceptor heteromers with antagonistic receptor–receptor
interactions may be a widespread mechanism in the CNS for
integration of galanin and noradrenaline (NA) signals.
These antagonistic receptor–receptor interactions participate
in the regulation of pre- and postjunctional central NA transmis-
sion and many antidepressant drugs exert part of their therapeutic
effects by increasing NA transmission via blockade of the NA
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transporter (Carlsson et al., 1966, 1969). Thus, these antago-
nistic GalR/α2-adrenoreceptor interactions are of relevance for
depression and its treatment.
In the NA cell bodies, dendrites and terminal networks the α2-
adrenoreceptor function as NA autoreceptors reducing NA cell
ﬁring and NA release from the terminal networks. At this level
this interaction will therefore favor increases in NA release and
thus NA transmission. At the postjunctional level this antago-
nistic interaction found all over the tel- and diencephalon will
change the balance of the pattern of NA isoreceptor activation
and favor the increased activation of beta-adrenergic receptor and
α1-adrenoreceptor subtypes. In view of the calming inﬂuence of
α2-adrenoreceptors at the behavioral level (see Fuxe et al., 2012b)
the preferential activation of the other adrenergic receptor sub-
types by galanin through the antagonisticGalR/α2-adrenoreceptor
interaction may result in increased arousal. It will therefore be
interesting to explore how this interaction may be altered in
the locus coeruleus and in the limbic networks in models of
depression.
EXISTENCE OF DopamineR–galaninR HETEROMERS IN THE
VENTRAL HIPPOCAMPUS
There exists evidence for the existence of D1R–GalR1 and D5R–
GalR1 heteromers in cellular models and D1-like receptors upon
agonist-induced activation were shown to enhance the GalR1-
induced MAPK signaling (Moreno et al., 2011). D1-like receptor
antagonists blocked galanin-induced MAPK activation in the ven-
tral hippocampus and in synaptosomes from this region galanin
facilitated acetylcholine release upon co-activation of the D1-like
receptors. Thus facilitatory allosteric D1-like-GalR interactions
in heteromers may exist in control of hippocampal acetylcholine
release and electrophysiological experiments in hippocampal slices
using ﬁeld EPSP recordings suggest a modulatory role of the
dopamineR–galaninR heteromers in cholinergic neurotransmis-
sion (Moreno et al., 2011).
CONCLUSIONS
GalR subtypes may have a major role in modulating the emotional
networks of the brain through heteromerization with 5-HT1A,
NPYY1, and α2-adrenoreceptors leading to antagonistic allosteric
receptor–receptor interactions producing reductions in 5-HT1A,
NPYY1, and α2-adrenoreceptor pre and especially postsynaptic
signaling in the central 5-HT and NA neurons. This may be one
way in which the activity at certain GalR subtypes and at galanin
fragment preferring receptors may contribute to a reduction of
mood, which may lead to depression. The GalR heteromers also
participate in cardiovascular functions, food intake and regulation
of fear and anxiety. The hypothesis is introduced that the galanin
fragment preferring receptor is formed by the GalR1–GalR2 het-
eromer which can mediate the strong depressant actions of Gal
1-15 upon intraventricular injections. Its postulated formation of
a trimer with 5-HT1A receptors may represent a novel target for
antidepressant drugs.
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